PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies

Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin

doi:10.1016/j.eururo.2017.10.027

PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies

Eur Urol. 2018 Apr;73(4):485-487. doi: 10.1016/j.eururo.2017.10.027. Epub 2017 Nov 11.

Authors

Steven P Rowe¹, Kenneth J Pienta², Martin G Pomper³, Michael A Gorin³

Affiliations

¹ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: srowe8@jhmi.edu.
² The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

The use of [¹⁸F]- and [⁶⁸Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.

Publication types

Editorial

MeSH terms

Fluorine Radioisotopes / pharmacology
Gallium Radioisotopes / pharmacology
Humans
Male
Positron-Emission Tomography / methods*
Prostate / diagnostic imaging*
Prostate-Specific Antigen / antagonists & inhibitors*
Prostatic Neoplasms / diagnosis*
Radiopharmaceuticals / pharmacology
Research Design / standards*
Sensitivity and Specificity

Substances

Fluorine Radioisotopes
Gallium Radioisotopes
Radiopharmaceuticals
Prostate-Specific Antigen

Grants and funding

R01 CA134675/CA/NCI NIH HHS/United States